Lantheus Medical Imaging: SPECT MPI with Cardiolite(R) Used in BARI 2D Study to Evaluate Type 2 Diabetes and Coronary Artery Disease Treatment Strategies

N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, announced today that the company’s leading imaging agent, Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), was used in a recently completed five-year study examining appropriate treatment regimens for patients with type 2 diabetes and coronary artery disease. The results of this study, known as The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D), will be presented by the University of Pittsburgh Graduate School of Public Health at a special symposium on Sunday, June 7, 2009, from 4:15 p.m. - 5:15 p.m. (CT) at the American Diabetes Association 69th Scientific Sessions in New Orleans.